CAJ | 학술논문

目的：观察临床常规剂量瑞舒伐他汀和阿托伐他汀对缺血性卒中患者的血脂的达标率和安全性的影响。方法选择100例缺血性卒中患者，年龄40～75周岁，LDL-C基线水平平均在4.2 mmol/L 以上的患者随机分为A、B两组，每组50例，A组患者服用常规剂量瑞舒伐他汀（10 mg），B组患者服用常规剂量阿托伐他汀（20 mg）；分别于治疗前后一个月后观察LDL-C变化并统计LDL＜1.8 mmol/L患者比例。结果两组在LDL-C等各项指标上差异有统计学意义（P＜0.05），且A组指标优于B组（P＜0.05）。A组：LDL＜1.8 mmol/L患者比例为72.30%，B组：LDL＜1.8 mmol/L患者比例为54.20%，且两组相比差异具有统计学意义（P＜0.05）。结论瑞舒伐他汀能使更多的缺血性卒中患者血脂达标，且安全性良好。
목적：관찰림상상규제량서서벌타정화아탁벌타정대결혈성졸중환자적혈지적체표솔화안전성적영향。방법선택100례결혈성졸중환자，년령40～75주세，LDL-C기선수평평균재4.2 mmol/L 이상적환자수궤분위A、B량조，매조50례，A조환자복용상규제량서서벌타정（10 mg），B조환자복용상규제량아탁벌타정（20 mg）；분별우치료전후일개월후관찰LDL-C변화병통계LDL＜1.8 mmol/L환자비례。결과량조재LDL-C등각항지표상차이유통계학의의（P＜0.05），차A조지표우우B조（P＜0.05）。A조：LDL＜1.8 mmol/L환자비례위72.30%，B조：LDL＜1.8 mmol/L환자비례위54.20%，차량조상비차이구유통계학의의（P＜0.05）。결론서서벌타정능사경다적결혈성졸중환자혈지체표，차안전성량호。
Objective To evaluate the blood lipid compliance rate and safety of atorvastatin and atorvastatin in the treatment of ischemic stroke. Methods 100 cases of ischemic stroke patients were selected, the ages were 40 to 75 and the LDL-C baseline averaged more than 4.2 mmol/L, they were randomly divided into group A and group B, 50 cases in each group, group A of patients were treated with conventional doses of rosuvastatin atorvastatin (10 mg) and group B were treated with conventional doses of atorvastatin (20 mg). The changes of LDL-C were observed and the number of patients LDL<1.8 mmol/L were counted before and one month after treatment. Results The differences of LDL-C and other indexes between two groups were statistically signiifcant (P<0.05) and group A was signiifcantly better than that of group B (P<0.05). The proportion of patients LDL<1.8mmol/L in group A 72.30%was much higher than that of group B 54.20%, The difference between the two groups was statistically signiifcant (P<0.05). Conclusion Rosuvastatin can make more ischemic stroke patients reach lipid standards, and it also very safe..